 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...112113114115116117118119120121122123124» |
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date: KEYNOTE 524: A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma (clinicaltrials.gov) - Sep 24, 2018
P1b, N=104, Recruiting, Sponsor: Eisai Co., Ltd.
Trial completion date: Dec 2020 --> Mar 2021
- | Trial completion date, Trial primary completion date, Monotherapy, Metastases: Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) (clinicaltrials.gov) - Sep 24, 2018
P1, N=408, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Dec 2020 --> Mar 2021 Trial completion date: Mar 2021 --> Jul 2021 | Trial primary completion date: Mar 2021 --> Jul 2021
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: CLEAR trial: Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Sep 13, 2018
P3, N=707, Recruiting, Sponsor: Eisai Inc.
Trial completion date: Mar 2021 --> Jul 2021 | Trial primary completion date: Mar 2021 --> Jul 2021 Trial completion date: Jan 2020 --> Feb 2021 | Trial primary completion date: Oct 2019 --> Apr 2020
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date: Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung (clinicaltrials.gov) - Sep 7, 2018
P2, N=25, Completed, Sponsor: Eisai Co., Ltd.
Trial completion date: Jan 2020 --> Feb 2021 | Trial primary completion date: Oct 2019 --> Apr 2020 Trial completion date: Oct 2016 --> Dec 2017
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion, Trial completion date, Trial primary completion date: Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding (clinicaltrials.gov) - Sep 6, 2018
P1, N=54, Completed, Sponsor: Eisai Inc.
Trial completion date: Oct 2016 --> Dec 2017 Recruiting --> Completed | Trial completion date: Aug 2018 --> Jul 2017 | Trial primary completion date: Feb 2018 --> Jul 2017
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change, Trial completion date, Trial primary completion date: KEYNOTE-146: A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors (clinicaltrials.gov) - Sep 4, 2018
P1b/2, N=329, Recruiting, Sponsor: Eisai Inc.
Recruiting --> Completed | Trial completion date: Aug 2018 --> Jul 2017 | Trial primary completion date: Feb 2018 --> Jul 2017 N=191 --> 329 | Trial completion date: Feb 2020 --> May 2019 | Trial primary completion date: Aug 2019 --> May 2019
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment change: Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) (clinicaltrials.gov) - Aug 31, 2018
P1, N=400, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=191 --> 329 | Trial completion date: Feb 2020 --> May 2019 | Trial primary completion date: Aug 2019 --> May 2019 N=180 --> 400
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date: Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy (clinicaltrials.gov) - Aug 28, 2018
P2, N=26, Active, not recruiting, Sponsor: Eisai Co., Ltd.
N=180 --> 400 Trial completion date: Aug 2018 --> Feb 2019 | Trial primary completion date: Aug 2018 --> Feb 2019
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change, Trial completion date, Trial primary completion date: Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma (clinicaltrials.gov) - Aug 21, 2018
P1/2, N=75, Recruiting, Sponsor: Eisai Limited
Trial completion date: Aug 2018 --> Feb 2019 | Trial primary completion date: Aug 2018 --> Feb 2019 N=108 --> 75 | Trial completion date: Sep 2018 --> Dec 2019 | Trial primary completion date: Jun 2018 --> Dec 2019
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial initiation date, Combination therapy: Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors (clinicaltrials.gov) - Aug 21, 2018
P1/2, N=132, Recruiting, Sponsor: Eisai Inc.
N=108 --> 75 | Trial completion date: Sep 2018 --> Dec 2019 | Trial primary completion date: Jun 2018 --> Dec 2019 Trial completion date: Dec 2022 --> May 2022 | Initiation date: Aug 2017 --> Nov 2017
- | Lenvima (lenvatinib) / Eisai, Merck (MSD), Lynparza (olaparib) / Merck (MSD), AstraZeneca, favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
Enrollment open: Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) (clinicaltrials.gov) - Aug 21, 2018
P3, N=2300, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Dec 2022 --> May 2022 | Initiation date: Aug 2017 --> Nov 2017 Not yet recruiting --> Recruiting
- | Caprelsa (vandetanib) / Sanofi, Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Exelixis
New P2 trial, Metastases: Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer (clinicaltrials.gov) - Aug 13, 2018
P2, N=45, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- | Review, Journal: Emerging therapies in advanced hepatocellular carcinoma. (Pubmed Central) - Aug 9, 2018
Advanced HCC patients are difficult to treat with poor outcomes. After initial approval of sorafenib in 2007, we recently have multiple new agents that showed benefit and promising activity, and are set to change the landscape of HCC treatment.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial initiation date, Metastases: Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - Aug 8, 2018
P2, N=13, Not yet recruiting, Sponsor: Yousef Zakharia
After initial approval of sorafenib in 2007, we recently have multiple new agents that showed benefit and promising activity, and are set to change the landscape of HCC treatment. Initiation date: Jul 2018 --> Oct 2018
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change, Trial completion date, Trial primary completion date: KEYNOTE 524: A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma (clinicaltrials.gov) - Aug 6, 2018
P1b, N=104, Recruiting, Sponsor: Eisai Co., Ltd.
Initiation date: Jul 2018 --> Oct 2018 N=30 --> 104 | Trial completion date: Feb 2019 --> Dec 2020 | Trial primary completion date: Aug 2018 --> Aug 2019
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change, Trial completion date, Trial initiation date, Trial withdrawal, Trial primary completion date, Pan tumor, Metastases: Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling (clinicaltrials.gov) - Aug 2, 2018
P2, N=0, Withdrawn, Sponsor: Teresa Helsten, MD
N=30 --> 104 | Trial completion date: Feb 2019 --> Dec 2020 | Trial primary completion date: Aug 2018 --> Aug 2019 N=39 --> 0 | Trial completion date: Jun 2019 --> Jun 2021 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2018 --> Jun 2020 | Initiation date: Jun 2016 --> Jul 2018
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Trial completion date, Trial primary completion date, Metastases: Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) (clinicaltrials.gov) - Aug 2, 2018
P3, N=780, Recruiting, Sponsor: Eisai Inc.
N=39 --> 0 | Trial completion date: Jun 2019 --> Jun 2021 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2018 --> Jun 2020 | Initiation date: Jun 2016 --> Jul 2018 Not yet recruiting --> Recruiting | Trial completion date: Jan 2022 --> Jan 2023 | Trial primary completion date: Nov 2021 --> Feb 2022
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: EPOC1706: Lenvatinib and Pembrolizumab Simultaneous Combination Study (clinicaltrials.gov) - Aug 1, 2018
P2, N=29, Not yet recruiting, Sponsor: National Cancer Center Hospital East
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion: Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung (clinicaltrials.gov) - Jul 26, 2018
P2, N=25, Completed, Sponsor: Eisai Co., Ltd.
Not yet recruiting --> Recruiting | Trial completion date: Jan 2022 --> Jan 2023 | Trial primary completion date: Nov 2021 --> Feb 2022 Active, not recruiting --> Completed
- | Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Metastases: LEADER: Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 26, 2018
P1/2, N=30, Recruiting, Sponsor: National Taiwan University Hospital
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | MK-4830 / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Monotherapy, Metastases: Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001) (clinicaltrials.gov) - Jul 19, 2018
P1, N=70, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date: Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T) (clinicaltrials.gov) - Jul 11, 2018
P=N/A, N=400, Recruiting, Sponsor: Eisai Co., Ltd.
Not yet recruiting --> Recruiting Trial completion date: Mar 2026 --> Mar 2025
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date: KEYNOTE 523: Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors (clinicaltrials.gov) - Jul 10, 2018
P1b, N=6, Active, not recruiting, Sponsor: Eisai Co., Ltd.
Trial completion date: Mar 2026 --> Mar 2025 Trial completion date: Jun 2018 --> Dec 2018 | Trial primary completion date: Jun 2018 --> Dec 2018
- ||||| Lenvima (lenvatinib) / Eisai, Merck (MSD), Lynparza (olaparib) / Merck (MSD), AstraZeneca, favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
Trial initiation date: Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) (clinicaltrials.gov) - Jul 6, 2018
P3, N=2300, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Jun 2018 --> Dec 2018 | Trial primary completion date: Jun 2018 --> Dec 2018 Initiation date: May 2018 --> Aug 2018
- || Keytruda (pembrolizumab) / Merck (MSD)
Biomarker, Trial initiation date, Tumor mutational burden, PD(L)-1 Biomarker: KeyImPaCT: A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) (clinicaltrials.gov) - Jul 6, 2018
P2, N=192, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
Initiation date: May 2018 --> Aug 2018 Initiation date: Jul 2018 --> Dec 2018
- | lenvatinib / Generic mfg.
Clinical, Review, Journal: Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review. (Pubmed Central) - Jul 3, 2018
Potential mechanisms for development of these rare adverse effects, as well as cases in which these adverse effects are seen with use of other tyrosine-kinase inhibitors will be presented. It is important to continue to report these side effects, and further studies are needed to elucidate potential risk factors for their development, as well as to determine prognosis after development.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P4 trial, Metastases: A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer (clinicaltrials.gov) - Jun 28, 2018
P4, N=50, Recruiting, Sponsor: Eisai Inc.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma (clinicaltrials.gov) - Jun 26, 2018
P2, N=33, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
It is important to continue to report these side effects, and further studies are needed to elucidate potential risk factors for their development, as well as to determine prognosis after development. Trial completion date: May 2018 --> May 2019 | Trial primary completion date: May 2018 --> May 2019
- ||| MK-4830 / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
New P1 trial, Monotherapy, Metastases: Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001) (clinicaltrials.gov) - Jun 21, 2018
P1, N=70, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- || Enrollment change, Monotherapy, Metastases: Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) (clinicaltrials.gov) - Jun 20, 2018
P1, N=340, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: May 2018 --> May 2019 | Trial primary completion date: May 2018 --> May 2019 N=240 --> 340
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open: A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile (clinicaltrials.gov) - Jun 15, 2018
P2, N=152, Recruiting, Sponsor: Eisai Inc.
N=240 --> 340 Active, not recruiting --> Recruiting
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date: Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy (clinicaltrials.gov) - May 31, 2018
P2, N=26, Active, not recruiting, Sponsor: Eisai Co., Ltd.
Active, not recruiting --> Recruiting Trial completion date: Oct 2017 --> Aug 2018 | Trial primary completion date: Jul 2017 --> Aug 2018
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date: Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - May 31, 2018
P1, N=25, Active, not recruiting, Sponsor: Eisai Co., Ltd.
Trial completion date: Oct 2017 --> Aug 2018 | Trial primary completion date: Jul 2017 --> Aug 2018 Trial completion date: Jun 2018 --> Sep 2018
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial: Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil (clinicaltrials.gov) - May 27, 2018
P=N/A, N=0, Approved for marketing, Sponsor: Eisai Inc.
- | Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1/2 trial, Metastases: LEADER: Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - May 18, 2018
P1/2, N=30, Not yet recruiting, Sponsor: National Taiwan University Hospital
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1 trial, Metastases: Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov) - May 15, 2018
P1, N=16, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- ||||| Keytruda (pembrolizumab) / Merck (MSD)
Biomarker, New P1/2 trial, New P2 trial, Tumor mutational burden, PD(L)-1 Biomarker: KeyImPaCT: A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) (clinicaltrials.gov) - May 8, 2018
P1/2, N=288, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P3 trial, Metastases: Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) (clinicaltrials.gov) - May 8, 2018
P3, N=780, Not yet recruiting, Sponsor: Eisai Inc.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial initiation date, Metastases: Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - May 1, 2018
P2, N=13, Not yet recruiting, Sponsor: Yousef Zakharia
Trial completion date: Jun 2018 --> Sep 2018 Initiation date: Mar 2018 --> Jul 2018
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date: Post-Marketing Surveillance of Lenvima in Korean Patients (clinicaltrials.gov) - Apr 27, 2018
P=N/A, N=3000, Recruiting, Sponsor: Eisai Korea Inc.
Initiation date: Mar 2018 --> Jul 2018 Trial completion date: Jul 2021 --> Oct 2021 | Trial primary completion date: Jul 2021 --> Oct 2021
- |||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open: Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC) (clinicaltrials.gov) - Apr 25, 2018
P2, N=100, Recruiting, Sponsor: Eisai Inc.
Trial completion date: Jul 2021 --> Oct 2021 | Trial primary completion date: Jul 2021 --> Oct 2021 Not yet recruiting --> Recruiting
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Combination therapy: Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer (clinicaltrials.gov) - Apr 22, 2018
P2, N=30, Not yet recruiting, Sponsor: Emory University
- | varlitinib (ASLAN001) / ASLAN Pharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1 trial, Metastases: Phase 1b of ASLAN001 (Varlitinib) in Patients With Advanced/ Metastatic Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Apr 17, 2018
P1b, N=22, Recruiting, Sponsor: National University Hospital, Singapore
- Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: Eribulin and Lenvatinib in Advanced Solid Tumors (clinicaltrials.gov) - Apr 4, 2018
P2, N=39, Recruiting, Sponsor: Virginia G. Kaklamani
Not yet recruiting --> Recruiting Trial completion date: Jan 2018 --> Mar 2019 | Trial primary completion date: Jan 2018 --> Mar 2019
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD), Lynparza (olaparib) / Merck (MSD), AstraZeneca, favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
New P3 trial: Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) (clinicaltrials.gov) - Apr 2, 2018
P3, N=2300, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- || Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed: Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) (clinicaltrials.gov) - Mar 30, 2018
P1, N=180, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Jan 2018 --> Mar 2019 | Trial primary completion date: Jan 2018 --> Mar 2019 Recruiting --> Active, not recruiting
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Trial completion date, Trial primary completion date, PD(L)-1 Biomarker: Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) (clinicaltrials.gov) - Mar 29, 2018
P2, N=60, Recruiting, Sponsor: Academic and Community Cancer Research United
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Trial completion date: Sep 2018 --> Sep 2022 | Trial primary completion date: Sep 2018 --> Sep 2020
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Monotherapy: Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials (clinicaltrials.gov) - Mar 26, 2018
P2, N=50, Not yet recruiting, Sponsor: Eisai Inc.
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed: A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile (clinicaltrials.gov) - Mar 21, 2018
P2, N=152, Active, not recruiting, Sponsor: Eisai Inc.
Not yet recruiting --> Recruiting | Trial completion date: Sep 2018 --> Sep 2022 | Trial primary completion date: Sep 2018 --> Sep 2020 Recruiting --> Active, not recruiting
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - Mar 16, 2018
P1, N=7, Terminated, Sponsor: Eisai Co., Ltd.
Recruiting --> Active, not recruiting Trial completion date: Sep 2017 --> May 2017 | Trial primary completion date: Sep 2017 --> May 2017